Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Radoff-JEC Group (owners of ~7.5% of SEER) sent an open letter to Seer (NASDAQ: SEER) on February 23, 2026, pressing for immediate governance and operational change.
The letter cites a >96% share price decline since Seer’s 2020 IPO, 2025 revenue midpoint of $17.5M, cumulative cash used in operations of $138.8M and capex of $11.4M (total cash use $150.2M), a market cap of $110.5M vs. $251.2M net cash, and CEO Omid Farokhzad’s reported total compensation of $24.9M (2021–2024).
Seer (NASDAQ: SEER) will participate in US HUPO 2026 in St. Louis, Feb 21–25, showcasing the Proteograph Product Suite across posters, oral sessions, and a breakfast symposium on Feb 24. Presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and population-scale proteomics, highlighting deep, scalable nanoparticle-enabled proteomics.
Speakers include Sasha A. Singh, Nathan Basisty, Bruce Wilcox, and Mozhgan Boroumand; Singh reports quantifying >5,000 proteins from 75 µL plasma per sample.
Seer (Nasdaq: SEER) will participate in the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026. Management will take part in a fireside chat at 11:10 a.m. ET, with a live webcast and archived replay available on the company website.
Seer (Nasdaq: SEER) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Management will host a live webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and an archived replay will be available on the company investor website.
Seer (NASDAQ: SEER) announced a Nature Genetics study (Nov 2025) validating its Proteograph product suite for population-scale, peptide-level mass spectrometry proteomics. The GWAS profiled ~1,600 blood samples (discovery n=1,260; replication n=325), detecting 5,753 proteins and quantifying 1,980 in ≥80% of participants. Researchers identified 364 pQTLs, 102 replicated, and 35 novel signals. The study found up to one-third of affinity-based pQTLs from single platforms failed mass spectrometry replication, showing peptide-level measurement reduces epitope-related artifacts and improves confidence for drug-target and biomarker discovery.
Implication: peptide-level MS can distinguish true protein regulation from assay artifacts, strengthening translational proteogenomics.
Seer (Nasdaq: SEER) announced new data to be presented at the Human Proteome Organization (HUPO) World Congress 2025 on Nov 10–12, 2025. More than a dozen scientific presentations—including two invited talks in Seer’s breakfast symposium on Nov 10, 2025—showcase the Proteograph® platform applied across cardiovascular, oncology, and aging biology.
Highlights include deep plasma and tissue proteomics identifying candidate biomarkers for right ventricular failure, aging-related mediators from mouse serum, and multi-cancer and extracellular vesicle proteome studies, underscoring scalability and translational potential for population-scale research.
Seer (Nasdaq: SEER) reported third-quarter 2025 results for the period ended September 30, 2025. Revenue was $4.1 million, up 2% year-over-year, with product revenue $2.8 million and service revenue $1.2 million (including $300k related-party). Gross profit was $2.1 million and gross margin 51%. Operating expenses were $21.5 million; net loss was $18.2 million. Cash, cash equivalents and investments totaled approximately $251.2 million as of September 30, 2025. Seer reiterated full-year 2025 revenue guidance of $17–$18 million (midpoint +24% vs. 2024). The company noted nearly three times more instrument shipments year-to-date vs. 2024 and a record >60 third-party publications.
A webcast and conference call are scheduled for November 6, 2025 at 1:30 PM PT.
Seer (Nasdaq: SEER) announced that company management will participate in two investor conferences in November 2025: the UBS Global Healthcare Conference in Palm Beach Gardens, FL with 1x1 meetings on Wednesday, November 12, 2025, and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York with a fireside chat on Thursday, November 20, 2025 at 4:00 p.m. ET. Live webcasts will be available on the company's investor site investor.seer.bio, and archived replays will be posted on the company website after each conference.
Seer (Nasdaq: SEER) will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will stream on the Investor section of the company website at investor.seer.bio, and an archived replay will be posted on the website after the event.
Seer (Nasdaq: SEER) will present at the American Society of Human Genetics (ASHG) Annual Meeting, October 14-18, 2025 in Boston, highlighting how proteomics complements genomics to advance precision medicine.
Seer will host a featured CoLab session on October 16, 2025, 2:30-3:00 p.m. ET showcasing Proteograph-enabled multi-omic studies, including xenotransplantation immune profiling and isoform-specific biomarkers in idiopathic pulmonary fibrosis. Multiple independent research groups will also present Proteograph-generated findings on October 16 across poster and session formats, illustrating adoption of Seer’s Proteograph Product Suite for proteogenomic discovery and biomarker identification.